SCOPUS 정보 검색 플랫폼

Drugs of the Future

Volumn 28, Issue 5, 2003, Pages 432-434

Laronidase: Treatment of mucopolysaccharidosis I

(1) McIntyre, J A a

a PROUS SCIENCE (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; LARONIDASE; LEVO IDURONIDASE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AIRWAY OBSTRUCTION; ANAPHYLAXIS; ANIMAL CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CAT; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; DRUG UPTAKE; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; GENETIC CODE; HEADACHE; HISTOLOGY; HUMAN; HUMAN CELL; HURLER SYNDROME; INJECTION SITE; LUNG FUNCTION; MOLECULAR CLONING; NONHUMAN; ORGAN SIZE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN MANIFESTATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

EID: 0042473314 PISSN: 03778282 EISSN: None Source Type: Journal
DOI: 10.1358/dof.2003.028.05.733789 Document Type: Article

Times cited : (2)

References (7)

1
- 0042533312
- Genzyme Press Release April 30
- BioMarin, Genzyme announce FDA marketing approval for Aldurazyme. Genzyme Press Release April 30, 2003.
- (2003) BioMarin, Genzyme Announce FDA Marketing Approval for Aldurazyme

2
- 0035905889
- Enzyme-replacement therapy in mucopolysaccharidosis I
- Kakkis, E.D., Muenzer, J., Tiller, G.E. et al. Enzyme-replacement therapy in mucopolysaccharidosis I. New Engl J Med 2001, 344: 182-8.
- (2001) New Engl J Med , vol.344 , pp. 182-188
- Kakkis, E.D.¹ Muenzer, J.² Tiller, G.E.³

3
- 0028449393
- Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells
- Kakkis, E.D., Matynia, A., Jonas, A.J., Neufeld, E.F. Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells. Protein Expr Purif 1994, 5: 225-32.
- (1994) Protein Expr Purif , vol.5 , pp. 225-232
- Kakkis, E.D.¹ Matynia, A.² Jonas, A.J.³ Neufeld, E.F.⁴

4
- 0035718871
- Enzyme replacement therapy in feline mucopolysaccharidosis I
- Kakkis, E.D., Schuchman, E., He, X. et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001, 72: 199-208.
- (2001) Mol Genet Metab , vol.72 , pp. 199-208
- Kakkis, E.D.¹ Schuchman, E.² He, X.³

5
- 0028568013
- Enzyme replacement in a canine model of Hurler syndrome
- Shull, R.M., Kakkis, E.D., McEntee, M.F., Kania, S.A., Jonas, A.J., Neufeld, E.F. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA 1994, 91: 12937-41.
- (1994) Proc Natl Acad Sci USA , vol.91 , pp. 12937-12941
- Shull, R.M.¹ Kakkis, E.D.² McEntee, M.F.³ Kania, S.A.⁴ Jonas, A.J.⁵ Neufeld, E.F.⁶

6
- 0030221033
- Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I
- Kakkis, E.D., McEntee, M.F., Schmidtchen, A., Neufeld, E.F., Ward, D.A., Gompf, R.E., Kania, S., Bedolla, C., Chien, S.-L., Shull, R.M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 1996, 58: 156-67.
- (1996) Biochem Mol Med , vol.58 , pp. 156-167
- Kakkis, E.D.¹ McEntee, M.F.² Schmidtchen, A.³ Neufeld, E.F.⁴ Ward, D.A.⁵ Gompf, R.E.⁶ Kania, S.⁷ Bedolla, C.⁸ Chien, S.-L.⁹ Shull, R.M.¹⁰

7
- 0042533311
- Additional primary endpoint data released from phase III Aldurazyme study
- November 26
- Additional primary endpoint data released from phase III Aldurazyme study. DailyDrugNews.com (Daily Essentials) November 26, 2002.
- (2002) DailyDrugNews.com (Daily Essentials)

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.